Recent news on Carbidopa

Treating restless leg syndrome  -  May 11, 2007
Cincinnati Post,An alternative drug treatment for patients unable to tolerate a dopamine agonist such as Requip is levodopa/carbidopa (Sinemet) 25/100.

Submission of NDA for Istradefylline(KW-6002), an investigational ...  -  May 1, 2007
News-Medical.net,Based on the clinical efficacy and safety data obtained, the company submitted a NDA for Istradefylline(KW-6002) as adjunctive therapy to levodopa/carbidopa

Not about getting old ...  -  Apr 28, 2007
Malaysia Star,Dr Chew said a new three-in-one drug comprising a pharmacokinetically enhanced levodopa therapy comprising levodopa, carbidopa and entacapone was available

Kyowa Hakko Kogyo submits NDA for Parkinson's drug  -  Apr 30, 2007
Pharma Times (subscription),...which has a specific antagonistic action on the adenosine A2A receptor in the brain, as adjunctive therapy to levodopa and carbidopa.

Lonnie Ali Champions 'Fight For MORE' Campaign  -  Apr 26, 2007
PR Newswire (press release),Doctors may recommend adding Zelapar to levodopa/carbidopa treatment when patients are experiencing a reduced response to this therapy.

Abbott pulls out of developing Orion's Simdax in the USA  -  Apr 26, 2007
Pharma Times (subscription),Once again sales were driven by its Parkinson's disease drug Stalevo (carbidopa, levodopa and entacapone) - sold with partner Novartis - which increased 3%

Lonnie Ali Champions 'Fight For MORE' Campaign  -  26 Apr 2007
PR Newswire (press release),Doctors may recommend adding Zelapar to levodopa/carbidopa treatment when patients are experiencing a reduced response to this therapy.

Abbott pulls out of developing Orion's Simdax in the USA  -  26 Apr 2007
Pharma Times (subscription),Once again sales were driven by its Parkinson's disease drug Stalevo (carbidopa, levodopa and entacapone) - sold with partner Novartis - which increased 3%

7 Companies Searching to Cure Parkinson's  -  26 Apr 2007
Seeking Alpha,...a once-daily adjunct therapy for Parkinson’s disease patients being treated with levodopa/carbidopa. It has a forward P/E of 16.6 and a PEG of .8.

ORION: Orion Group Interim Report 1-3/2007  -  Apr 25, 2007
Kauppalehti (press release),The combined net sales of Orion's proprietary products for Parkinson's Disease, Stalevo (levodopa, entacapone, carbidopa) and Comtess/Comtan (entacapone)

FDA announces withdrawal of Parkinson's drug  -  Mar 29, 2007
Indianapolis Star,Pergolide is in a class of medications called dopamine agonists and is used with levodopa and carbidopa to manage the symptoms - tremors and slowness of

FDA Announces Withdrawal of Parkinson’s Drug from Market  -  Mar 30, 2007
Newsinferno.com,Pergolide is a dopamine agonist and is used in conjunction with levodopa and carbidopa to manage the symptoms (tremors, slowness of movement) of Parkinson’s

Medialink Features: Using a Diary Card to Manage Parkinson's ...  -  Feb 15, 2007
PR Newswire (press release),Stalevo is one of the most recent advancements in levodopa therapy since the introduction of levodopa/carbidopa in the 1970s. For the full story,

Orion Oyj: Orion group financial review (proforma) 1-12/2006  -  Feb 6, 2007
Kauppalehti (press release),In the study, Stalevo is compared with conventional levodopa/carbidopa medication. The study, under way since late 2004, is being carried out in

TRx Pharma introduces FOLMOR for treatment of cardiovascular disease  -  Feb 7, 2007
Carolina Newswire (press release),FOLMOR can be given to patients taking both carbidopa and levodopa. Concurrent use of phenytoin and folic acid may decrease the effectiveness of phenytoin,

Portion of Orion profits may go towards new Simdax study  -  Feb 7, 2007
Pharma Times (subscription),Once again sales were driven by its Parkinson's disease drug Stalevo (carbidopa, levodopa and entacapone) - sold with partner Novartis - which increased

Vitamin B6: immunity star, or not?  -  Feb 5, 2007
Health24.com,...penicillamine which is used to treat rheumatoid arthritis, and anti-parkinsonism drugs such as benserazide and carbidopa (Garrow et al, 2000).

Gambling problem can affect restless legs patients  -  Jan 31, 2007
Scientific American...drugs commonly used for one or both conditions include Requip (generic name ropinirole), Mirapex (pramipexole) and Sinemet (levodopa plus carbidopa).

IMPAX Files Amendment to Vadovaâ„¢ NDA  -  18 Jan 2007
Business Wire (press release),Vadova has the potential to be a valuable addition to current carbidopa/levodopa treatments for Parkinson’s disease.�

Enduring life's lists  -  Dec 31, 2006
Sarasota Herald-Tribune,Keppra, Depakote, Risperdal, Carbidopa, Topamax, Termazepan. Not to mention the occasional aspirin. He carries a timer that cues him to take his next dose

Unusual drug mixture inhibits tumors in mice  09 Nov 2006
Two drugs — amiloride, a diuretic, and carbidopa, used to treat Parkinson's disease — exert their effects by inhibiting the same mechanisms the research ... -Washington University Record, ORION: Stalevo improves quality of life with Parkinson's disease ...  Oct 31, 2006
...(2) About Stalevo Stalevo (levodopa/carbidopa/entacapone) is an enhanced levodopa therapy for the treatment of Parkinson's disease indicated for those patients ... -Kauppalehti (press release), Citing Limbaugh, Fox 31 misled on Michael J. Fox stem cell ad  Oct 26, 2006
...stop working.". Carbidopa/Levodopa (Sinemet) Levodopa is a substance that is converted into dopamine by an enzyme in the brain. It ... -Media Matters for America, New Evidence Demonstrates Use of Stalevo Improves Quality of Life ...  Nov 1, 2006
Stalevo (levodopa/carbidopa/entacapone) is an enhanced levodopa therapy for the treatment of Parkinson's disease indicated for those patients experiencing ... -DG News Insight Into Dopamine Role Suggests New Treatment Pathway For ...  Oct 18, 2006
...blocked its synthesis. And conversely, they could quickly restore dopamine by administering a mix of L-Dopa and carbidopa. To analyze ... -Science Daily (press release) Parkinson's patients find hope  Oct 10, 2006
The procedure stimulates the same parts of the brain that are affected by the most common Parkinson's drug, Carbidopa/Levodopa, known by the brand name, Sinemet ... -Kentucky Post, New Analyses Further Support Benefits Of Once-Daily AZILECT(R) In ...  Oct 11, 2006
...subgroup analysis showed that once-daily AZILECT(R) as adjunct treatment produced additional symptomatic benefits when added to levodopa/carbidopa therapy and ... -Medical News Today (press release), Unusual Three-drug Combo Inhibits Growth Of Aggressive Tumors  Sep 10, 2006
Two drugs - amiloride, a diuretic, and carbidopa, used to treat Parkinson's disease - exert their effects by inhibiting the very same mechanisms the research ... -Medical News Today

Vernalis Plc: Interim Results for the Six Months Ended 30 June ...  Sep 11, 2006
Parkinson's Disease V1512 is an innovative, patented effervescent formulation combining levodopa methylester, a more soluble form of levodopa, and carbidopa. ... -PR Newswire

New Therapy For Parkinson's Disease Patients  Sep 6, 2006
Levodopa/carbidopa is commonly used early in the treatment of Parkinson's disease, but as the disease progresses it becomes increasingly difficult to ... -Western Queens Gazette

FDA Approvals: Zelapar and Prezista  Aug 24, 2006
...disintegrating tablets for the adjunctive treatment of Parkinson's disease in patients who exhibit deterioration of response to levodopa/carbidopa therapy; and ... -Medscape (subscription)

After the Diagnosis: Managing Parkinson’s Disease  Aug 15, 2006
Sinemet contains levodopa, combined with carbidopa. ... A medication called Stalevo combines entacapone with levodopa and carbidopa. ... -ITP.net

Orion Oyj: Orion group financial review 1-6/2006  Aug 7, 2006
The favourable progress was driven by the flagship products, Stalevo (levodopa, entacapone, carbidopa) and Comtess/Comtan (entacapone), Orion’s proprietary ... -Kauppalehti

Valeant Pharma Reveals Availability Of Zelapar For Parkinson's ...  Jul 18, 2006
...which was approved by the US Food and Drug Administration as a once-daily adjunct therapy for Parkinson's disease patients being treated with levodopa/carbidopa ... -Trading Markets

Valeant Pharmaceuticals Announces Availability of Zelapar(R) for ...  Jul 18, 2006
...the US Food and Drug Administration (FDA) on June14, 2006 as a once-daily adjunct therapy for Parkinson's diseasepatients being treated with levodopa/carbidopa ... -Finanzen.net

Valeant Pharma Launches Parkinson's Disease Tablet Zelapar In US ...  Jul 18, 2006
...by the US Food and Drug Administration on June 14 as a once-daily adjunct therapy for Parkinson's disease patients being treated with levodopa/carbidopa. ... -Trading Markets

Unfaltering hope for miracle  Jul 9, 2006
...ding, ding. He still takes the drug carbidopa-levodopa, which is converted to dopamine in the brain, but not as often. Within five ... -Columbus Dispatch

IMPAX Announces the Launch of IMPAX Pharmaceuticals; Company's ...  Jul 11, 2006
IMPAX Laboratories has several products at various stages of development including Vadova(TM) (carbidopa and levodopa), which is under review by the US Food ... -Business Wire



Orion Oyj: Orion group interim report 1-3/2006  May 8, 2006
...and Comtess/Comtan accounted for one-third of the net sales The proprietary Parkinson’s Disease products Stalevo (levodopa, entacapone, carbidopa) and Comtess ... - Kauppalehti





New laboratory approach to treat Parkinson’s  Mar 27, 2006
A number of chemicals such as carbidopa, work by slowing the conversion of levodopa to dopamine in the bloodstream so that more of it reaches the brain. ... - LabTechnologist.com

Impax receives US FDA non-approvable letter for Vadova  Apr 6, 2006
...has received a non-approvable letter from the US Food and Drug Administration (FDA) concerning its new drug application for Vadova (carbidopa/levodopa) tablets ... - Therapeutics Daily (subscription)

Impax hit by FDA rejection of Parkinson's drug  Mar 8, 2006
Impax said it was uncertain whether it would ever be able to bring Vadova (carbidopa/levodopa) tablets to market, but would be seeking a meeting with FDA to ... - Pharma Times (subscription)

Valeant Pharmaceuticals Receives FDA Approval of Less-Restrictive ...  Feb 22, 2006
...tolcapone), the company's COMT (catechol-O-methyltransferase) inhibitor product for Parkinson's disease patients undergoing treatment with levodopa/carbidopa. ... - Genetic Engineering News,

Orion Oyj: Orion group 2005 financial statements  Feb 9, 2006
...together with Novartis, launched a follow-up development, Stalevo®, which combines the standard treatment levodopa with entacapone and carbidopa, the two ... - Kauppalehti,

Orion Oyj: Orion group 2005 financial statements  09 Feb 2006
...together with Novartis, launched a follow-up development, Stalevo®, which combines the standard treatment levodopa with entacapone and carbidopa, the two ... - Kauppalehti

Mylan Reports Third Quarter Adjusted Diluted EPS of $0.25  Feb 2, 2006
Continued competition on certain products, primarily omeprazole, carbidopa/levodopa and Amnesteem(TM), was responsible for the overall unfavorable pricing and ... - MSN Money

International Approvals: Tasmar, Amplimexon, IV Remodulin  Jan 17, 2006
...and reversible catechol-O-methyltransferase (COMT) inhibitor is indicated for use in combination with levodopa/benserazide or levodopa/carbidopa in patients ... - Medscape (subscription)

One day at a time with Parkinson's  Jan 10, 2006
...developing a cure. Today, the most widely prescribed treatment is a combination of two drugs, Levodopa and Carbidopa. They are described ... - Globe and Mail

IMPAX Settles Patent Suit and Signs Marketing and Promotion ...  Jan 19, 2006
...target market for Carbatrol of approximately 8,300 neurologists in the US overlaps with the Company's target market for Vadova(TM) (carbidopa and levodopa). ... - Genetic Engineering News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional